Apiject to open new generic injectable drug facility in North Carolina

USA—Apiject Holdings, Inc. has signed a lease for a 30,000-square-foot pharmaceutical manufacturing facility in Apex, North Carolina, marking a significant step toward restoring domestic control over essential medicines.

The facility will house two advanced Blow-Fill-Seal (BFS) production lines and will operate as an FDA-registered 503B outsourcing facility dedicated to producing critical generic injectable medicines currently appearing on the FDA’s drug shortage list.

Additionally, the site will serve as the corporate headquarters of Vanguard Utility, Apiject’s operational subsidiary.

The Apex facility represents the latest milestone in Apiject’s comprehensive effort to strengthen U.S. pharmaceutical manufacturing capabilities.

The company recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its first BFS-based prefilled injection device, achieving a major regulatory breakthrough for the platform.

This progress demonstrates the company’s commitment to translating advanced American manufacturing technology into tangible domestic production capacity.

The investment directly addresses national priorities to reshore critical manufacturing infrastructure and strengthen resilience in key industries, particularly in the pharmaceutical sector.

At a time when the United States faces persistent drug shortages and heavy reliance on foreign pharmaceutical suppliers, initiatives like this carry strategic importance beyond commercial considerations.

Jay Walker, Chairman of Apiject, emphasized that America’s dependence on foreign sources for essential medicines creates a strategic vulnerability that demands immediate attention.

He positioned pharmaceutical manufacturing alongside energy independence and rare earth mineral production as critical areas requiring domestic control.

Walker described the Apex facility as the next phase in Apiject’s ongoing mission to transform advanced manufacturing technology into reliable domestic production capabilities.

The United States currently confronts two urgent challenges in generic drug supply that threaten healthcare security.

More than 200 drugs regularly appear on the FDA’s shortage list, creating gaps in patient care and forcing healthcare providers to seek alternatives.

Despite generic drugs accounting for approximately 90 percent of U.S. prescriptions, an estimated 70 to 80 percent of these medications are manufactured in China and India.

This overwhelming foreign dependence exposes the American healthcare system to significant risks during emergencies, supply chain disruptions, and geopolitical tensions.

Apiject’s manufacturing strategy centers on advanced Blow-Fill-Seal technology, which the pharmaceutical industry has historically used primarily for eyedrops and inhalation products.

With support from the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, Apiject has pioneered significant advancements that expand BFS capabilities into a standardized, high-speed platform suitable for most liquid injectable medicines.

The BFS process offers distinct advantages over traditional glass vial packaging methods.

While conventional packaging relies on complex global supply chains and lengthy production timelines involving multiple steps and suppliers, BFS forms the drug container, fills the medicine, and seals the dose in one continuous automated process.

The technology depends on a single, domestically available raw material, completely eliminating reliance on fragile foreign glass supply chains that have proven vulnerable to disruptions.

Darren Alkins, CEO of Vanguard Utility, explained that BFS fundamentally transforms the economics of generic injectable drug manufacturing.

He noted that Apiject’s technological advancements now enable BFS to produce a broad range of liquid injectable medicines quickly, at scale, and at globally competitive costs entirely within the United States for both domestic and international markets.

The company has reinforced its progress through strategic commercial partnerships, including licensing agreements with corporate partners to advance sterile BFS manufacturing capabilities for injectable medicines across the United States.

Operating under the FDA’s 503B pathway, the Apex facility will prioritize producing generic shortage-listed injectable medicines, enabling faster deployment of essential drugs manufactured domestically.

This represents a competitive advantage that offshore producers cannot replicate due to shipping times and regulatory constraints.

Apiject acknowledged the White House’s leadership and ASPR’s critical role in supporting advanced manufacturing approaches that strengthen U.S. public health preparedness and industrial resilience.

Walker emphasized that restoring U.S. manufacturing capacity for essential medicines requires both sustained policy leadership and continuous technological innovation.

He expressed appreciation for the Administration’s commitment to rebuilding American industrial capabilities and supporting platforms that make domestic production both viable and resilient in the face of global uncertainties.